Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer
The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the cl...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 February 2014
|
| In: |
Breast cancer research and treatment
Year: 2014, Jahrgang: 144, Heft: 2, Pages: 353-360 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-014-2853-6 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10549-014-2853-6 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007%2Fs10549-014-2853-6 |
| Verfasserangaben: | Ines Gruber, Tanja Fehm, Florin Andrei Taran, Markus Wallwiener, Markus Hahn, Diethelm Wallwiener, Natalia Krawzyck, Juergen Hoffmann, Andreas Daniel Hartkopf |
| Zusammenfassung: | The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the clinical impact of DTC-persistence. |
|---|---|
| Beschreibung: | Gesehen am 21.08.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-014-2853-6 |